Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2003 Dec;5(6):466-72.
doi: 10.1007/s11906-003-0054-5.

Metalloproteinases and plasminogen activators in vessel remodeling

Affiliations
Review

Metalloproteinases and plasminogen activators in vessel remodeling

Alex Bobik et al. Curr Hypertens Rep. 2003 Dec.

Abstract

Remodeling of blood vessels underlies the pathogenesis of major cardiovascular disorders, including atherosclerosis, restenosis, and hypertension. Because remodeling of arteries is highly dependent on degradation of the extracellular matrix, which enables cells to migrate and proliferate, there is intense interest in the regulation and the roles of matrix metalloproteinases (MMPs) and the plasminogen activator-plasmin (PA-P) systems in vessel remodeling. Factors that promote vessel remodeling have been shown to be important in upregulating the activities of both proteolytic systems and include chronic changes in hemodynamics, vessel injury, cytokines involved in inflammation, and elevations in reactive oxygen species. The two proteolytic systems utilize common transcription factors to activate their respective genes and are frequently coexpressed in remodeling and atherosclerotic arteries. In this review, we discuss the effects of activating the MMP and PA-P systems on processes involved in vascular remodeling, factors regulating their expression and activation, their roles in restenosis, and the development and progression of atherosclerosis, as well as the ability of currently available inhibitors to prevent unfavorable remodeling and atherosclerosis.

PubMed Disclaimer

References

    1. FEBS Lett. 1996 Feb 26;381(1-2):21-4 - PubMed
    1. J Cell Biol. 2001 Sep 3;154(5):1069-79 - PubMed
    1. Circulation. 1995 Sep 15;92(6):1565-9 - PubMed
    1. Lab Invest. 1999 Apr;79(4):407-16 - PubMed
    1. Circulation. 1999 Apr 13;99(14 ):1788-94 - PubMed

MeSH terms

LinkOut - more resources